01NextCure reported Q3 earnings per share of -$1.29, missing the consensus estimate of -$0.90 by $0.39 per share on November 10, 2026.
02The 43% earnings miss represents a notable deviation that often triggers analyst revisions and influences institutional positioning.
03NextCure's stock trades at $5.55 with a market capitalization of $30.1M following the earnings release.
04The company has missed earnings estimates in two consecutive quarters, with Q2 showing a 44.3% miss and Q3 showing a 43.3% miss.
Earnings Results
NextCure (NASDAQ:NXTC) reported quarterly earnings results on November 10, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-1.29, missing the consensus estimate of $-0.90 by $0.39 per share. Revenue came in at , meeting the estimate of .
Company Overview
NextCure's stock moved following the earnings release. The stock currently trades at $5.55 with a market capitalization of $30.1M.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 43% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking NextCure should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.